Metal Resurfacing Implants (HemiCAP) - Salvage Procedure

→ When biological treatments fail, a metal cap can resurface the damaged area. Think of it like a dental crown for cartilage. It's a salvage option - a last-ditch effort before fusion/replacement.

What It Is

Metal resurfacing was proposed for large osteochondral defects not successfully treated with other surgical treatments. The HemiCAP implant is available in 15 articular component offset sizes based on medial talar dome anatomy [132].

Patient-Specific Talar Resurfacing: 24-Month Prospective Data (July 2026)

The Rizzoli Institute published the first prospective two-year series of a customized focal talar resurfacing implant, and it is the most directly relevant new surgical evidence of the month for a failed prior graft [217]:

• 40 patients screened, 20 implanted, 17 completed 24-month follow-up; Level II evidence
• FAOS improved from 58.6 ± 16.6 to 97.3 ± 4.9 at 24 months
• Pain at rest fell from 4.3 ± 2.7 to 0.0 ± 0.0; pain on activity from 6.8 ± 1.7 to 0.1 ± 0.3
• 17 of 20 returned to sport at a mean of 5.1 ± 3.2 months; mean return to work 4.2 ± 3.0 months
• 3 complications, 1 revision, 5% treatment-failure rate
• Why it matters here: focal metal inlay resurfacing is the established option specifically after failed prior cartilage surgery — the exact revision position of a 2012 fresh allograft that became symptomatic at 12 years. It resurfaces the defect without committing the joint to fusion or replacement
• Caveats: only 20 patients and 24 months. The abstract does not name the implant brand, and lesion sizes are not reported, so fit to a 15×10 mm defect with a 15×12×10 mm cyst is unconfirmed. This does not displace biologic revision options — it strengthens the fallback

Clinical Outcomes

Critical Technical Factors

Implantation accuracy is crucial [133]:

• Metal resurfacing can recover >90% of contact area when properly placed
• Warning: If implant protrudes by just 0.25 mm, peak contact stress increases by 220%
• Must be placed 0.5 mm below surrounding cartilage for proper compression

Patient-Specific Focal Resurfacing (Episealer Talus) — 2025

→ Unlike generic HemiCAP, Episealer is custom-manufactured from CT data to exactly match your talus surface. Think of it as a perfectly fitted metal patch instead of an off-the-shelf cap.

A 2025 technique paper frames Episealer as a solution for the "treatment gap": active patients with focal talar defects in an otherwise healthy joint, or patients after failed primary treatment [155].

• Indications: Focal defect in otherwise preserved joint, or failed prior biological treatment
• Contraindications: Joint-space narrowing at Van Dijk stage ≥2, defects on opposing tibial surface

A 2025 multicenter series of 15 patients at 1-year follow-up [156]:

• Significant FAOS and pain improvement
• No revision to ankle replacement at 1 year
• Promising but still very early data

Concerns

• One study reported 50% revision rate with poor prognosis in patients with increased BMI
• The 2024 DGOU guidelines state: "Metallic resurfacing of OLT can only be recommended as a second-line treatment" [128]
• The 2024 revision systematic review found older HemiCAP-type procedures had the worst complication burden: 31 failures in 111 ankles (28%) [148]
• Long-term data shows opposing cartilage does not appear to break down (12-year follow-up)

Status: Salvage procedure for failed biological treatments. Not recommended as first-line. If moving to metal, patient-specific resurfacing (Episealer) is more current than generic HemiCAP, but only if joint space and tibial side are still preserved.

Availability correction, July 2026 — this page previously implied a domestic option that does not exist.

• The Episealer Talus has never been FDA cleared, and Episurf says so plainly. Its own product page states “Episealer Talus is not available in the United States.” Episurf holds exactly one US 510(k) — K221048, the Episealer Patellofemoral knee implant, December 2022. Pursuing this would mean being treated in Europe
• It is genuinely still on the market there. The EU device database (EUDAMED) lists it as on-the-market as of May 18, 2026, available in eleven countries including Germany, Sweden, Italy, France and Spain. Two clinical studies are live (Norway recruiting, Italy enrolled). This is a real, CE-marked, currently implantable device — not a discontinued one
• But it is made in one size only — 15 mm diameter — which is a hard constraint to check against a ~15 × 10 mm lesion before travelling anywhere
• Its corporate owner has decided it does not belong in the company. On April 20, 2026 Episurf announced a dual-track process to move its entire medtech business outside the group by the end of 2026, by sale or distribution to shareholders. The parent has meanwhile absorbed more than SEK 2 billion of real estate and diluted itself roughly fourfold; medtech revenue was SEK 3.0 million in Q1 2026. The company is not bankrupt, renamed, or delisted — but who owns and supports this implant in 2027 is unknown
• Two open risks. European sales moved to a distributor model in 2025, so access depends on whether a distributor covers a given country. And Episurf's devices remain CE-marked under the old Medical Device Directive; the company states its MDR dossier was submitted for the Knee first and does not mention the Talus. Class IIb implantables face a hard MDR deadline of December 31, 2027
• The Talus post-market study (NCT06225674) has been listed status-unknown since January 2024, past its estimated completion, with no results posted

None of this bears on the implant clinically — the 24-month patient-specific resurfacing outcomes below are unaffected and the concept remains sound. The correct reading is not “this option is gone” but “this option is a European referral with a two-to-three-year ownership question attached, and a size check to do first.” The decision point to watch is Episurf's Q2 report on August 24, 2026 and any dual-track outcome before year end.

What else exists for the talus — and what has quietly disappeared

→ Checked in July 2026. Two options this page used to list are no longer manufactured, and the US alternatives replace the whole talus rather than resurfacing part of it.

• Arthrex Ankle Spacer — discontinued. Firmly sourced: its own clinical trial (NCT03303690) was terminated in 2020 with the stated reason that Arthrex stopped manufacturing the device. It never held a 510(k)
• Arthrosurface HemiCAP Talus — apparently discontinued and never FDA cleared. Arthrosurface has 26 US clearances, none for the ankle or talus. Anika divested Arthrosurface in October 2024 and the retained portfolio is knee, shoulder, wrist and toe — ankle absent. The current Arthrosurface ankle page lists only a soft-tissue allograft. No formal discontinuation notice was found, so this is inference from the record rather than a statement
• The US options are total talus replacements under Humanitarian Device Exemption, not focal resurfacing. Paragon 28's Patient Specific Talus Spacer (H200001, now Zimmer Biomet) and 4WEB/Stryker's device (H240001) are both indicated for avascular necrosis only. restor3d's Total Talus Replacement (H230003) is the exception worth knowing about: its instructions for use explicitly cover “large, uncontained, unstable, or cystic talar osteochondral defects… not responsive to traditional treatments” — language that describes this lesion. But it removes the entire talus, and it is contraindicated where the tibiotalar, subtalar or talonavicular joints show degenerative change. That makes it a late-salvage option, not an alternative to resurfacing

Net: the Episealer Talus appears to be the only patient-specific focal talar resurfacing implant commercially available anywhere, and it is Europe-only. Everything available in the US either replaces the whole bone or is indicated for a different disease.

Added August 26, 2026 — a second patient-specific focal implant is being built, aimed at exactly the gap this page documents

→ Dutch researchers announced they are developing a custom 3D-printed titanium implant — called AMPLANK — specifically for ankle cartilage damage in young, active patients, designed to fit the ankle’s tight space without removing healthy bone. It is at the computer-simulation and prototype stage: real, aimed at the right problem, and years from a patient.

The section above ends with this page’s standing complaint: one focal resurfacing implant exists, in one size, in Europe, at a company trying to sell the business. An August 14 announcement from the University of Twente describes a project building the second entrant [444]: AMPLANK, a patient-specific 3D-printed titanium implant for ankle cartilage damage, developed by Twente (Athena Jalalian) with Radboudumc (Dennis Janssen), the Sint Maartenskliniek — one of the Netherlands’ highest-volume orthopaedic hospitals — a Fraunhofer innovation platform, and industrial partners. The stated design goals read like a response to this page’s ledger: custom-fit to each patient’s anatomy (against Episealer’s single 15 mm size), sized for the ankle’s confined space, sparing healthy bone (against the US total-talus route), and explicitly targeted at “young and active patients, for whom current treatment options are often far from ideal”.

Where it actually is: preclinical prototype development — the announced plan is computer simulation of implant behavior, then anatomical fit testing, with surgical-technique development alongside; no trial is registered, no timeline to clinical use is given, and no patient has received one. This entry is a watch item, not an option. Its value here is directional: a serious academic–clinical consortium has independently concluded that patient-specific focal metal resurfacing of the ankle is a gap worth building for — which is both a vote for the concept this page tracks and, eventually, a possible successor if the Episealer’s commercial limbo ends badly. Watch for: a registered first-in-human trial (likely on the Dutch trial register or CT.gov), or the project’s first peer-reviewed simulation/cadaver paper.

Added September 5, 2026 — the “Italy enrolled” Episealer study now has a name, a design, and an overdue readout

→ This page has known since July that an Italian Episealer study existed, but only as a one-line mention in the EU device database. It surfaced in full this week: Rizzoli in Bologna implanted the Episealer Talus in 20 patients between 2021 and 2023 and is following them for five years. The one-year data has existed since late 2023 — meaning a paper could appear at any time. This is now the largest known prospective Episealer Talus cohort.

The July availability audit above noted “two clinical studies are live (Norway recruiting, Italy enrolled)” — the Norwegian trial was pinned as [379], the Italian one was an EUDAMED phrase. A September 1 record-verification update pushed the Italian study through this week’s registry window and it is now on the ledger [459]: NCT06522139, IRCCS Istituto Ortopedico Rizzoli (Bologna) — a prospective, single-group, interventional study of the Episealer Talus for osteochondral lesions of the talus: 20 patients (actual, not estimated), implanted October 2021 – September 2023, primary endpoints of FAOS pain/symptoms and implant survival, follow-up running to an estimated August 2027. Retrospectively registered in July 2024, status ACTIVE_NOT_RECRUITING — not joinable, but that is not its value here.

Why this matters to this page: the Episealer Talus evidence base has been a 15-patient multicenter 1-year series [156], a technique paper [155], and a sponsor post-market study that has been status-unknown since January 2024 (NCT06225674). This is the first independent, academic, registered prospective cohort — at the hospital whose group this site already watches for two other trials — and its primary completion date passed in September 2023, so the 1-year FAOS/survival readout exists and is publishable now. With Episurf’s corporate dual-track resolving by end of 2026 and the MDR deadline behind it, an independent Rizzoli outcome paper is exactly the piece of evidence that would tell a prospective patient whether the device is worth a European referral. Registry watch opened (the sixteenth): status changes, results posting, or the publication itself.